FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293083559> ?p ?o ?g. }

• W4293083559 endingPage "111292" @default.
• W4293083559 startingPage "111292" @default.
• W4293083559 abstract "Adverse reactions, which are mostly local and rarely systemic, can be seen during subcutaneous immunotherapy (SCIT). It was not possible to continue SCIT at times due to systemic reactions. The purpose of the present study was to identify the incidence and risk factors associated with adverse reactions during subcutaneous allergen-specific immunotherapy (AIT).A total number of 344 patients under 18 years old with allergic rhinitis and/or asthma who underwent SCIT between 2005 and 2021 were included in the study. Demographic characteristics of the patients, laboratory findings [Total Immunglobulin E(IgE), aeroallergen prick test, inhaler, and allergen specific IgE(sIgE) and eosinophil counts], and adverse events observed during AIT were recorded retrospectively. Descriptive and univariate/multivariate logistic regression analyses were used to identify risk factors for adverse events.Among 344 patients, 33.4% (n = 115) were female, mean age was 133.1 ± 41.0 months, and 42.2% (n = 145) were >12 years old. One hundred-thirty eight (40.1%) of the patients were mono-sensitized, 47 (13.7%) had asthma, 207 (60.2%) allergic rhinitis, and 90 (26.2%) asthma and allergic rhinitis. Single allergen content was administered to 187 (54.4%) patients (62 mite, 114 grass mix, 11 olea), and multiple allergens to 157 (45.6%) patients (121 pollen mix, 36 other (mite/alternaria)]. A total number of 33.008 injections were administered. 840 adverse reactions (262 (31.1%) at up-dosing phase, 578 (68.8%) at maintenance phase) in 195 (56.7%) patients were observed. Among the adverse reactions, 632 (75.2%) were local, 160 (19%) large local, and 48 (5.7%) (39 at maintenance, 9 at up-dosing) (in 31 patients) were systemic (28 Grade 1, 12 Grade 2, 8 Grade 3). Adrenalin was administered to 8 patients with Grade 3 systemic reaction (8/33008; %0.024). Adverse reactions, especially local ones, were seen more frequently in children under 12 years old (p < 0.001). Patients sensitized with grass pollen (p:0.01) and mite (p:0.004), and those who had received SCIT with pollen mixture had more adverse reactions than the others. More adverse reactions were observed in SCIT containing calcium-phosphate as adjuvant (p: 0.01). Local reactions were risk factors for large local (OR = 3.591, %95 CI:2.064-6.247, p < 0.001) and systemic (OR = 2.190, %95 CI:1.005-4.722 p = 0.046) reactions at univariate analyses. Total nasal symptom scores, Visual Analog Scale and asthma symptom control test decreased after one year of treatment (p < 0.01).SCIT is a safe and effective treatment method in childhood that leads to improvements in all nasal symptoms and asthma after one year of treatment." @default.
• W4293083559 created "2022-08-26" @default.
• W4293083559 creator A5004954842 @default.
• W4293083559 creator A5008195255 @default.
• W4293083559 creator A5027245572 @default.
• W4293083559 creator A5030204691 @default.
• W4293083559 creator A5083234617 @default.
• W4293083559 date "2022-11-01" @default.
• W4293083559 modified "2023-10-06" @default.
• W4293083559 title "Effectiveness and adverse reactions to subcutaneous immunotherapy in children with allergic rhinitis/asthma" @default.
• W4293083559 cites W1969919155 @default.
• W4293083559 cites W1972551310 @default.
• W4293083559 cites W2000677412 @default.
• W4293083559 cites W2009267110 @default.
• W4293083559 cites W2019544390 @default.
• W4293083559 cites W2038405674 @default.
• W4293083559 cites W2065738222 @default.
• W4293083559 cites W2121760095 @default.
• W4293083559 cites W2157795773 @default.
• W4293083559 cites W2291471825 @default.
• W4293083559 cites W2332117994 @default.
• W4293083559 cites W2420358600 @default.
• W4293083559 cites W2520815795 @default.
• W4293083559 cites W2528005888 @default.
• W4293083559 cites W2586472050 @default.
• W4293083559 cites W2597931938 @default.
• W4293083559 cites W2614031938 @default.
• W4293083559 cites W2756993541 @default.
• W4293083559 cites W3008150919 @default.
• W4293083559 cites W3010397464 @default.
• W4293083559 cites W3017310149 @default.
• W4293083559 cites W3078830553 @default.
• W4293083559 cites W4225579819 @default.
• W4293083559 doi "https://doi.org/10.1016/j.ijporl.2022.111292" @default.
• W4293083559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36007303" @default.
• W4293083559 hasPublicationYear "2022" @default.
• W4293083559 type Work @default.
• W4293083559 citedByCount "2" @default.
• W4293083559 countsByYear W42930835592023 @default.
• W4293083559 crossrefType "journal-article" @default.
• W4293083559 hasAuthorship W4293083559A5004954842 @default.
• W4293083559 hasAuthorship W4293083559A5008195255 @default.
• W4293083559 hasAuthorship W4293083559A5027245572 @default.
• W4293083559 hasAuthorship W4293083559A5030204691 @default.
• W4293083559 hasAuthorship W4293083559A5083234617 @default.
• W4293083559 hasConcept C120665830 @default.
• W4293083559 hasConcept C121332964 @default.
• W4293083559 hasConcept C126322002 @default.
• W4293083559 hasConcept C141105273 @default.
• W4293083559 hasConcept C159654299 @default.
• W4293083559 hasConcept C197934379 @default.
• W4293083559 hasConcept C203014093 @default.
• W4293083559 hasConcept C207480886 @default.
• W4293083559 hasConcept C2776042228 @default.
• W4293083559 hasConcept C2778391694 @default.
• W4293083559 hasConcept C2779711295 @default.
• W4293083559 hasConcept C2779787640 @default.
• W4293083559 hasConcept C2780510475 @default.
• W4293083559 hasConcept C59822182 @default.
• W4293083559 hasConcept C61511704 @default.
• W4293083559 hasConcept C71924100 @default.
• W4293083559 hasConcept C86803240 @default.
• W4293083559 hasConceptScore W4293083559C120665830 @default.
• W4293083559 hasConceptScore W4293083559C121332964 @default.
• W4293083559 hasConceptScore W4293083559C126322002 @default.
• W4293083559 hasConceptScore W4293083559C141105273 @default.
• W4293083559 hasConceptScore W4293083559C159654299 @default.
• W4293083559 hasConceptScore W4293083559C197934379 @default.
• W4293083559 hasConceptScore W4293083559C203014093 @default.
• W4293083559 hasConceptScore W4293083559C207480886 @default.
• W4293083559 hasConceptScore W4293083559C2776042228 @default.
• W4293083559 hasConceptScore W4293083559C2778391694 @default.
• W4293083559 hasConceptScore W4293083559C2779711295 @default.
• W4293083559 hasConceptScore W4293083559C2779787640 @default.
• W4293083559 hasConceptScore W4293083559C2780510475 @default.
• W4293083559 hasConceptScore W4293083559C59822182 @default.
• W4293083559 hasConceptScore W4293083559C61511704 @default.
• W4293083559 hasConceptScore W4293083559C71924100 @default.
• W4293083559 hasConceptScore W4293083559C86803240 @default.
• W4293083559 hasLocation W42930835591 @default.
• W4293083559 hasLocation W42930835592 @default.
• W4293083559 hasOpenAccess W4293083559 @default.
• W4293083559 hasPrimaryLocation W42930835591 @default.
• W4293083559 hasRelatedWork W2000438593 @default.
• W4293083559 hasRelatedWork W2037019085 @default.
• W4293083559 hasRelatedWork W2054114633 @default.
• W4293083559 hasRelatedWork W2093685379 @default.
• W4293083559 hasRelatedWork W2135087799 @default.
• W4293083559 hasRelatedWork W2163024252 @default.
• W4293083559 hasRelatedWork W2179490639 @default.
• W4293083559 hasRelatedWork W2409357349 @default.
• W4293083559 hasRelatedWork W30803436 @default.
• W4293083559 hasRelatedWork W2166948011 @default.
• W4293083559 hasVolume "162" @default.
• W4293083559 isParatext "false" @default.
• W4293083559 isRetracted "false" @default.
• W4293083559 workType "article" @default.